cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Urogen Pharma Ltd
2 own
4 watching
Current Price
$10.64
$-0.07
(-0.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
585.81M
52-Week High
52-Week High
20.70000
52-Week Low
52-Week Low
10.51000
Average Volume
Average Volume
1.4M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization585.81M
icon52-Week High20.70000
icon52-Week Low10.51000
iconAverage Volume1.4M
iconDividend Yield--
iconP/E Ratio--
What does the Urogen Pharma Ltd do?
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company s lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Read More
How much money does Urogen Pharma Ltd make?
News & Events about Urogen Pharma Ltd.
Business Wire
1 year ago
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (RSUs) to 6 new employees in connection with their employment with...
Business Wire
1 year ago
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO (mitomycin) for...
Ticker Report
1 year ago
UroGen Pharma Ltd. (NASDAQ:URGN Get Rating) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 743,700 shares, an increase of 16.3% from the March 31st total of 639,500 shares. Based on an average daily trading ...
Business Wire
1 year ago
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO (mitomycin) for...
Business Wire
1 year ago
UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (RSUs) to 7 new employees in connection with their entering into...
Frequently Asked Questions
Frequently Asked Questions
What is Urogen Pharma Ltd share price today?
plus_minus_icon
Can Indians buy Urogen Pharma Ltd shares?
plus_minus_icon
How can I buy Urogen Pharma Ltd shares from India?
plus_minus_icon
Can Fractional shares of Urogen Pharma Ltd be purchased?
plus_minus_icon
What are the documents required to start investing in Urogen Pharma Ltd stocks?
plus_minus_icon
What is today’s traded volume of Urogen Pharma Ltd?
plus_minus_icon
What is today’s market capitalisation of Urogen Pharma Ltd?
plus_minus_icon
What is the 52-Week High and Low Range of Urogen Pharma Ltd?
plus_minus_icon
What percentage is Urogen Pharma Ltd down from its 52-Week High?
plus_minus_icon
What percentage is Urogen Pharma Ltd up from its 52-Week Low?
plus_minus_icon
Current Price
$10.64
$-0.07
(-0.65%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$7.45
$-0.37 (-4.73 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$14.99
$0.88 (6.24 %)
Taysha Gene Therapies Inc
Taysha Gene Therapies Inc
$1.85
$0.00 (0.00 %)
Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc.
$8.28
$-0.29 (-3.38 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
PHATHOM PHARMACEUTICALS INC
PHATHOM PHARMACEUTICALS INC
$7.45
$-0.37 (-4.73 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$14.99
$0.88 (6.24 %)
Taysha Gene Therapies Inc
Taysha Gene Therapies Inc
$1.85
$0.00 (0.00 %)
Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc.
$8.28
$-0.29 (-3.38 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00